A phase 3, open-label, randomized, allopurinol-controlled study to assess the long-term safety of oral febuxostat in subjects with gout.

Trial Profile

A phase 3, open-label, randomized, allopurinol-controlled study to assess the long-term safety of oral febuxostat in subjects with gout.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Allopurinol; Febuxostat
  • Indications Gout
  • Focus Registrational; Therapeutic Use
  • Acronyms EXCEL
  • Most Recent Events

    • 18 Nov 2008 Checked against ClinicalTrials.gov record.
    • 03 Sep 2008 Sponsor/affilliate changed from TAP Pharmaceuticals to Takeda Global Research and Development Centre as reported in ClinicalTrials.gov record.
    • 04 Oct 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top